53120-74-4

Usage

Uses

Used in Solvent Applications:
3,3-Dimethyl-1,5-pentanediol is used as a solvent for its ability to dissolve a wide range of substances, making it suitable for various industrial processes.
Used in Industrial and Consumer Product Production:
3,3-Dimethyl-1,5-pentanediol is used in the production of various industrial and consumer products due to its compatibility with different materials and its ability to enhance product performance.
Used in Polymer Synthesis:
3,3-Dimethyl-1,5-pentanediol is used as a component in the synthesis of certain polymers, contributing to the development of new materials with specific properties.
Used as a Plasticizer in Resin Systems:
3,3-Dimethyl-1,5-pentanediol is used as a plasticizer in some resin systems to improve flexibility, workability, and durability of the final product.
Used in Personal Care Product Formulation:
3,3-Dimethyl-1,5-pentanediol is used in the formulation of personal care products, such as lotions and creams, due to its moisturizing properties, enhancing the skin's hydration and softness.
Used in Safety and Toxicity Considerations:
3,3-Dimethyl-1,5-pentanediol is considered to have low toxicity and is generally considered safe for use in various applications, ensuring the well-being of consumers and the environment.

Upstream product

• 4839-46-7 3,3-Dimethylglutaric acid 
• 17804-59-0 diethyl 3,3-dimethylglutarate 
• 4160-82-1 3,3-dimethylglutaric anhydride 
• 61193-04-2 3-(R,S),5-(R,S)-3,5-dicyano-4,4-dimethyl-2,6-dioxopiperidine 
• 110-94-1 1,5-pentanedioic acid 
• 53120-75-5 3,3-dimethylglutaryl chloride 

Downstream Products

• 37746-17-1 1,5-dibromo-3,3-dimethylpentane 
• 53120-76-6 3,3-dimethylpentane-1,5-diyl bis(4-methylbenzenesulfonate) 
• 22791-80-6 4,4-dimethyl-tetrahydro-pyran-2-one 
• 156684-08-1 5-(tert-butyldiphenylsiloxy)-3,3-dimethyl-1-pentanol 
• 175143-80-3 1-benzyloxymethoxy-3,3-dimethyl-5-pentanol 
• 674-26-0 mevalonolactone 
• 39149-97-8 (Z)-3-methylpent-2-ene-1,5-diol 

Relevant academic research and scientific papers

Enantioselective Synthesis of N-Alkylamines through β-Amino C-H Functionalization Promoted by Cooperative Actions of B(C6F5)3and a Chiral Lewis Acid Co-Catalyst

We disclose a catalytic method for β-C(sp3)-H functionalization of N-alkylamines for the synthesis of enantiomerically enriched β-substituted amines, entities prevalent in pharmaceutical compounds and used to generate different families of chiral catalysts. We demonstrate that a catalyst system comprising of seemingly competitive Lewis acids, B(C6F5)3, and a chiral Mg- or Sc-based complex, promotes the highly enantioselective union of N-alkylamines and α,β-unsaturated compounds. An array of δ-amino carbonyl compounds was synthesized under redox-neutral conditions by enantioselective reaction of a N-alkylamine-derived enamine and an electrophile activated by the chiral Lewis acid co-catalyst. The utility of the approach is highlighted by late-stage β-C-H functionalization of bioactive amines. Investigations in regard to the mechanistic nuances of the catalytic processes are described.

A phosphine-free iron complex-catalyzed synthesis of cycloalkanes: Via the borrowing hydrogen strategy

Herein we report a diaminocyclopentadienone iron tricarbonyl complex catalyzed synthesis of substituted cyclopentane, cyclohexane and cycloheptane compounds using the borrowing hydrogen strategy in the presence of various substituted primary and secondary 1,n diols as alkylating reagents. Deuterium labeling experiments confirm that the diols were the hydride source in this cascade process. This journal is

3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF

The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.

N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE

The invention relates to heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.

Compounds and Their Use in Treating Cancer

The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts and prodrugs thereof, where R1, R4, R5, R6, R7, Linker, X, Y, A, G, D and E have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts and prodrugs thereof in methods of treatment of the human or animal body, for example in prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.

Stereoselective synthesis of alicyclic ketones: A hydrogen borrowing approach

A highly diastereoselective annulation strategy for the synthesis of alicyclic ketones from diols and pentamethylacetophenone is described. This process is mediated by a commercially available iridium(III) catalyst, and provides efficient access to a wide range of cyclopentane and cyclohexane products with high levels of stereoselectivity. The origins of diastereoselectivity in the annulation reaction have been explored by a series of control experiments, which provides an explanation for how each stereocentre around the newly forged ring is controlled.

PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS

The present disclosure provides, inter alia, Compounds of Formulae IA, IB, IC, IIA, IIB and IIC or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

SALT FORM AND CRYSTAL FORM OF 1,2,5-THIADIAZOLIDIN-1,1-DIOXIDE, PREPARATION METHOD THEREOF AND INTERMEDIATE

The present invention discloses a salt form, crystal form and intermediate of the compound 1, and preparation method thereof.

Stereoselective Synthesis of Cyclohexanes via an Iridium Catalyzed (5 + 1) Annulation Strategy

An iridium catalyzed method for the synthesis of functionalized cyclohexanes from methyl ketones and 1,5-diols is described. This process operates by two sequential hydrogen borrowing reactions, providing direct access to multisubstituted cyclic products with high levels of stereocontrol. This methodology represents a novel (5 + 1) strategy for the stereoselective construction of the cyclohexane core.

ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE

Disclosed is a novel anti-enterovirus 71 (EV71) 1,2,5-thiadiazolidine-1,1-dioxide derivative or a pharmaceutically acceptable salt thereof; and specifically, a compound represented by formula (II) or a pharmaceutically acceptable salt thereof.